Global Locations

Lifitegrast D4



Chemical Properties of 'Lifitegrast D4'

CAT No. :

CS-P-08463
CAS Registry No. : 1025967-78-5 (Unlabeled)
Category : Isotope Labelled Compounds
Molecular Weight: 619.50 g/mol
Molecular Formula : C29H20D4Cl2N2O7S



OTHER INFORMATION of 'Lifitegrast D4'
IUPAC Name :(2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
Solubility :Soluble
Use Classification :Human Drugs -> EU pediatric investigation plans
Hazard Class :Repr. 2 (100%)
EC Number :813-044-8
UNII :038E5L962W
RXCUI :1801820
MeSH Entry Terms :(2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid
Other Synonyms :Lifitegrast
Removed Synonyms :D04ISS
Label Ingredient : LIFITEGRAST
NDC Code :0078-0911-05, 0078-0911-12, 0078-0911-94, 0078-0911-95, 54092-606-01, 54092-606-02, 54092-606-04, 54092-606-06, 54092-606-07
Toxicity Summary :Some adverse effects in 5-25% of the patients include instillation site irritation, dysgeusia and reduced visual acuity. There is no evidence or reports of potential carcinogenic, mutagenic or fertility-altering effects of this drug.
Protein Binding :Human plasma protein binding of lifitegrast was approximately 99%, independent of concentration (50 to 1000ng/mL). Binding to isolated human serum albumin was 95% to 98%, and 31.6% to 51.1% to human α1-acid glycoprotein.
Exact Mass :614.0681277
InChI :InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
InchIKey :JFOZKMSJYSPYLN-QHCPKHFHSA-N
Canonical SMILES :CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
Isomeric SMILES :CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
Product Description :Lifitegrast is an N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3-(methanesulfonyl)-L-phenylalanine. Used for treatment of keratoconjunctivitis sicca (dry eye syndrome). It has a role as an anti-inflammatory drug and a lymphocyte function-associated antigen-1 antagonist. It is a L-phenylalanine derivative, a sulfone, a N-acyl-L-alpha-amino acid, a member of isoquinolines and a member of 1-benzofurans.
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back


Looking for a discounted price or need more info for 'Lifitegrast D4 (CS-P-08463)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Lifitegrast D4 (CS-P-08463)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.